ClinicalTrials.gg
CompletedNCT01136967Updated Nov 13, 2019Results posted

An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

A Phase 2 interventional study of Lenvatinib in Unresectable Stage III and Stage IV Melanoma, sponsored by Eisai Inc.. Completed at 95 sites in 4 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-11-13.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
182
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 18 studies testing lenvatinib in Melanoma — 3 open to participants now, 5 under way, none of them phase 3. lenvatinib · Melanoma.

Enrollment
3rd of 18
182 · median 41
Started
2010
with 1 other
Phase 2
12 of 18
3 open now
Registered
3rd of 18
by date
Lead sponsor
3 of 18
Eisai Inc.

Among the 18 studies testing lenvatinib in Melanoma, this one is the 3rd largest by enrollment, is one of 2 that started in 2010, is one of 12 in phase 2, and was the 3rd registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

3 of the 18 studies testing lenvatinib in Melanoma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing lenvatinib in Melanoma, or all of them as a file.
02

Study summary

The purpose of this study is to assess the objective response rate of lenvatinib in previously treated participants with American Joint Committee on Cancer (AJCC) unresectable Stage III or Stage IV melanoma and disease progression.

Read the detailed description

This was a Phase 2, multicenter, open-label, 2-cohort, 2-stage study that assessed the ORR of lenvatinib in previously treated participants with AJCC unresectable Stage III or Stage IV melanoma and disease progression. Cohort 1 enrolled participants not harboring the V600E BRAF mutation with disease progression following up to 2 prior systemic anticancer regimens (excluding anti-VEGF) for unresectable Stage III or Stage IV melanoma, and is referred to as Cohort 1 or V600E BRAF negative. Other less common BRAF activating mutations were allowed as long as the participant did not receive a BRAF-targeted therapy. Cohort 2 enrolled participants harboring the activating BRAF mutations (mainly the V600E mutation) with disease progression following BRAF V600E-targeted therapy, and is referred to as Cohort 2 or V600E BRAF positive. Eligible participants had measurable disease according to RECIST 1.1.

03

Conditions studied

  • Unresectable Stage III
  • Stage IV Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed diagnosis of melanoma.
  2. Unresectable Stage III or Stage IV melanoma.
  3. Evidence of disease progression according to 1.1 on prior regimen.
  4. Participants with will be eligible if they have undergone complete surgical excision and are more then 1 month post surgery with no radiographic evidence of disease recurrence in the brain or have undergone stereotactic radio surgery (gamma knife procedure) and are more then 1 month post procedure and with no radiographic evidence of disease progression in the brain; and are asymptomatic, and discontinued treatment at least 30 days prior starting treatment.
  5. (ECOG) performance status of 0 or 1.
  6. Adequately controlled blood pressure.
  7. Adequate renal function, bone marrow function, blood coagulation function, and liver function, as defined in the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Melanoma of intraocular origin.
  2. or except as for participants with brain metastases will be eligible if they have undergone complete surgical excision and are more then 1 month post surgery with no radiographic evidence of disease recurrence in the brain or have undergone stereotactic radio surgery (gamma knife procedure) and are more then 1 month post procedure and with no radiographic evidence of disease progression in the brain; and are asymptomatic, and discontinued treatment at least 30 days prior starting treatment.
  3. More than 2 prior systemic anticancer regimen treatments including immunotherapies for unresectable Stage III or Stage IV disease (if BRAF V600E mutation negative) or not previously treated with BRAF V600E-targeted therapy or received in the past more than 2 prior systemic anticancer regimen treatments, including immunotherapies, in addition to a BRAF-V600E-targeted therapy (if BRAF V600E mutation positive).
  4. Significant cardiovascular impairment.
  5. Bleeding disorder or a thrombotic disorder requiring anticoagulant therapy.
  6. Females who are pregnant or breastfeeding.
  7. Prolongation of to greater than 480 msec.
  8. 24 hour urine protein greater than or equal to 1 gm.
  9. Active hemoptysis within 3 wks prior to the first dose of study drug.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
182 participants (actual)

Study arms

  • Experimental
    Cohort 1 (V600E BRAF negative)

    Cohort 1 (V600E BRAF negative) enrolled participants not harboring the V600E BRAF mutation with disease progression following up to 2 prior systemic anticancer regimens (excluding anti-VEGF) for unresectable Stage III or Stage IV melanoma.

    Drug: Lenvatinib

  • Experimental
    Cohort 2 (V600E BRAF positive)

    Cohort 2 (V600E BRAF positive) enrolled participants harboring the activating BRAF mutations (mainly the V600E mutation) with disease progression following BRAF V600E-targeted therapy.

    Drug: Lenvatinib

Interventions

  • Participants received lenvatinib 24 mg orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.

    Also known as: E7080

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR, (ORR = CR + PR) was defined as the percentage of participants in each cohort who had a best overall response (BOR) of complete response (CR) or partial response (PR) based on Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 for target lesions assessed by magnetic resonance imaging/computed tomography (MRI/CT) scans and independent radiologic review (IRR). A BOR of CR required confirmation by a subsequent CR assessment at least 4 weeks later. A BOR of PR required confirmation by a subsequent assessment of CR or PR at least 4 weeks later. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to have a reduction in short axis to less than (\<)10 mm. PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From date of treatment start until all participants completed a minimum of 6 cycles (28-day cycles) or discontinued treatment prior to end of Cycle 6 (up to 24 weeks)

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS was measured as the time from the date of first administration of study treatment until the date of first documentation of disease progression or date of death from any cause (whichever occurred first), as determined by IRR and Investigator based on RECIST v1.1. Disease progression per RECIST v1.1 was defined as at least a 20% relative increase and 5 mm absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. PFS was analyzed using Kaplan-Meier (1958) product-limit estimates. Data were presented with 2-sided 95% confidence interval (CI) when an adequate number of at risk participants warranted the estimates in the table below.

    Time frame: From date of treatment start until documentation of disease progression or death from any cause (whichever occurred first) or up to data cutoff (Cohort 1; 15 Jan 2012 and Cohort 2; 15 Apr 2013), up to approximately 2 years 8 months

  2. Overall Survival (OS)

    OS was defined as the length of time in months from the date of first administration of study drug until the date of death from any cause, and was based on the data cutoff date for each cohort. OS was analyzed using Kaplan-Meier (1958) product-limit estimates. Data were presented with 2-sided 95% CI when an adequate number of at risk participants warranted the estimates in the table below.

    Time frame: From date of treatment start until date of death from any cause or up to data cutoff (Cohort 1; 15 Jan 2012 and Cohort 2; 15 Apr 2013), up to approximately 2 years 8 months

  3. Disease Control Rate (DCR)

    DCR, (DCR = CR + PR + SD) was defined as the percentage of participants who had a BOR of CR or PR or stable disease (SD) based on RECIST v1.1 for target lesions assessed by MRI/CT and IRR. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (target or non-target) had to have a reduction in short axis to \<10 mm.; PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; Overall Response (OR) = CR + PR. SD defined as reduction in tumor volume of \< 30% or an increase in the volume of 1 or more measurable lesions of \< 25% without the appearance of any new lesions which was neither tumor shrinkage corresponding to PR nor tumor expansion corresponding to disease progression. BOR of SD, time from first administration of study drug until date of documented SD needed to be \>=7 weeks based on IRR and Investigator's assessment.

    Time frame: From date of treatment start until documentation of disease progression or death from any cause (whichever occurred first) or up to data cutoff (Cohort 1; 15 Jan 2012 and Cohort 2; 15 Apr 2013), up to approximately 2 years 8 months

  4. Clinical Benefit Rate (CBR)

    CBR, (CBR = CR + PR + durable SD rate) was defined as the percentage of participants who had a BOR of CR or PR or durable SD (dSD, SD lasting \>=23 weeks) based on RECIST v1.1 for target lesions assessed by MRI/CT, IRR and Investigator's assessment. A BOR of CR required confirmation by a subsequent CR assessment at least 4 weeks later. A BOR of PR required confirmation by a subsequent assessment of CR or PR at least 4 weeks later. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (target or non-target) had to have a reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; OR = CR + PR. A BOR of dSD, the time from the first administration of study drug until the date of documented dSD needed to be ≥23 weeks based on IRR and Investigator's assessment.

    Time frame: From date of treatment start until documentation of disease progression or death from any cause (whichever occurred first) or up to data cutoff (Cohort 1; 15 Jan 2012 and Cohort 2; 15 Apr 2013), up to approximately 2 years 8 months

  5. Number of Participants With Adverse Events (AEs)/ Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Lenvatinib

    Safety was assessed by monitoring and recording all AEs including all Common Terminology Criteria for Adverse Events (CTCAE) grades and SAEs; regular monitoring of hematology, clinical chemistry, and urine values; physical examinations; and regular measurement of vital signs, electrocardiograms (ECGs), and multi-gated acquisition (MUGA) scans or echocardiogram.

    Time frame: From date of treatment start up to 30 days after the last dose, or up to data cutoff (Cohort 1; 15 Jan 2012 and Cohort 2; 15 Apr 2013), up to approximately 2 years 9 months

  6. Change From Baseline in the Concentration of Clinical Biomarkers in Whole Blood

    Blood samples were drawn at specific time points. Utilizing a standard protocol, the deoxyribonucleic acid (DNA) from whole blood was extracted and analyzed for specific biomarkers of absorption, distribution, metabolism, and excretion of lenvatinib. Some of the biomarkers analyzed included; Angiopoietin, Epidermal Growth Factor (EGF), Fibroblast Growth Factor (FGF), FMS Like Tyrosine Kinase 3 Ligand (Flt3l) Granulocyte Colony Stimulating Factor (G-CSF), Granulocyte Macro Colony Stimulating Factor (GM-CSF), Interleukin 1 Receptor Antagonist (IL-1RA), Interferon (IFN), Macrophage Inflammatory Protein (MIP) 1 alpha, Platelet Derived Growth Factor (PDGF), Stromal Cell Derived Factor (SDF) 1 alpha, Interleukin (IL), Transforming Growth Factor (TGF), Tumor Necrosis Factor (TNF), Vascular Endothelial Growth Factor (VEGF).

    Time frame: Cycle 1 Day 15 (C1 D15), Cycle 2 Day 1 (C2 D1), Cycle 3 Day 1 (C3 D1), Off-Treatment/Phase Visit 98 (V98)

  7. Summary of Plasma Concentration of Lenvatinib

    Blood samples for the quantification of lenvatinib in plasma were obtained and processed using a standardized protocol. The lower limit of quantification was 0.25 ng/mL. Pharmacokinetic (PK) analysis was conducted using nonlinear mixed effects modeling. Descriptive statistics were used to summarize lenvatinib plasma concentration data.

    Time frame: Predose and 2 to 12 hours postdose at Cycle 1 Day 1 (C1D1), Cycle 1 Day 15 (C1D15), and Cycle 2 Day 1 (C2D1)

07

Results

Posted Mar 16, 2016

Participant flow

A total of 298 participants were screened. Of these, 116 were screen failures and 182 received treatment (93 participants in Cohort 1 and 89 participants in Cohort 2).

Participant flow — Overall Study
MilestoneCohort 1 (V600E BRAF Negative)Cohort 2 (V600E BRAF Positive)
Started9389
Disease progression5556
Treatment ongoing at data cutoff146
Completed6962
Not completed2427
Withdrew: Adverse event912
Withdrew: Participant choice83
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject12
Withdrew: Clinical progression35
Withdrew: Radiation10
Withdrew: Non-compliance10
Withdrew: Investigator's choice11
Withdrew: Increase in lesion size02
Withdrew: Diagnosis of second primary cancer01

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR, (ORR = CR + PR) was defined as the percentage of participants in each cohort who had a best overall response (BOR) of complete response (CR) or partial response (PR) based on Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 for target lesions assessed by magnetic resonance imaging/computed tomography (MRI/CT) scans and independent radiologic review (IRR). A BOR of CR required confirmation by a subsequent CR assessment at least 4 weeks later. A BOR of PR required confirmation by a subsequent assessment of CR or PR at least 4 weeks later. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to have a reduction in short axis to less than (\<)10 mm. PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From date of treatment start until all participants completed a minimum of 6 cycles (28-day cycles) or discontinued treatment prior to end of Cycle 6 (up to 24 weeks)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsCohort 1 (V600E BRAF Negative)Cohort 2 (V600E BRAF Positive)
Objective Response Rate (ORR)8.6 (3.8 to 16.2)9.0 (4.0 to 16.9)
SecondaryProgression Free Survival (PFS)

PFS was measured as the time from the date of first administration of study treatment until the date of first documentation of disease progression or date of death from any cause (whichever occurred first), as determined by IRR and Investigator based on RECIST v1.1. Disease progression per RECIST v1.1 was defined as at least a 20% relative increase and 5 mm absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. PFS was analyzed using Kaplan-Meier (1958) product-limit estimates. Data were presented with 2-sided 95% confidence interval (CI) when an adequate number of at risk participants warranted the estimates in the table below.

Time frame:
From date of treatment start until documentation of disease progression or death from any cause (whichever occurred first) or up to data cutoff (Cohort 1; 15 Jan 2012 and Cohort 2; 15 Apr 2013), up to approximately 2 years 8 months
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsCohort 1 (V600E BRAF Negative)Cohort 2 (V600E BRAF Positive)
Determined by IRR3.7 (2.5 to 4.2)1.8 (1.8 to 2.2)
Determined by Investigator3.7 (3.6 to 4.2)2.3 (1.9 to 3.4)
SecondaryOverall Survival (OS)

OS was defined as the length of time in months from the date of first administration of study drug until the date of death from any cause, and was based on the data cutoff date for each cohort. OS was analyzed using Kaplan-Meier (1958) product-limit estimates. Data were presented with 2-sided 95% CI when an adequate number of at risk participants warranted the estimates in the table below.

Time frame:
From date of treatment start until date of death from any cause or up to data cutoff (Cohort 1; 15 Jan 2012 and Cohort 2; 15 Apr 2013), up to approximately 2 years 8 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsCohort 1 (V600E BRAF Negative)Cohort 2 (V600E BRAF Positive)
Overall Survival (OS)8.9 (8.3 to NA)6.3 (5.2 to 8.8)
SecondaryDisease Control Rate (DCR)

DCR, (DCR = CR + PR + SD) was defined as the percentage of participants who had a BOR of CR or PR or stable disease (SD) based on RECIST v1.1 for target lesions assessed by MRI/CT and IRR. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (target or non-target) had to have a reduction in short axis to \<10 mm.; PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; Overall Response (OR) = CR + PR. SD defined as reduction in tumor volume of \< 30% or an increase in the volume of 1 or more measurable lesions of \< 25% without the appearance of any new lesions which was neither tumor shrinkage corresponding to PR nor tumor expansion corresponding to disease progression. BOR of SD, time from first administration of study drug until date of documented SD needed to be \>=7 weeks based on IRR and Investigator's assessment.

Time frame:
From date of treatment start until documentation of disease progression or death from any cause (whichever occurred first) or up to data cutoff (Cohort 1; 15 Jan 2012 and Cohort 2; 15 Apr 2013), up to approximately 2 years 8 months
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR)
Percentage of participantsCohort 1 (V600E BRAF Negative)Cohort 2 (V600E BRAF Positive)
Determined by IRR52.7 (42.1 to 63.1)34.8 (25.0 to 45.7)
Determined by Investigator64.5 (53.9 to 74.2)48.3 (37.6 to 59.2)
SecondaryClinical Benefit Rate (CBR)

CBR, (CBR = CR + PR + durable SD rate) was defined as the percentage of participants who had a BOR of CR or PR or durable SD (dSD, SD lasting \>=23 weeks) based on RECIST v1.1 for target lesions assessed by MRI/CT, IRR and Investigator's assessment. A BOR of CR required confirmation by a subsequent CR assessment at least 4 weeks later. A BOR of PR required confirmation by a subsequent assessment of CR or PR at least 4 weeks later. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (target or non-target) had to have a reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; OR = CR + PR. A BOR of dSD, the time from the first administration of study drug until the date of documented dSD needed to be ≥23 weeks based on IRR and Investigator's assessment.

Time frame:
From date of treatment start until documentation of disease progression or death from any cause (whichever occurred first) or up to data cutoff (Cohort 1; 15 Jan 2012 and Cohort 2; 15 Apr 2013), up to approximately 2 years 8 months
Reported as:
Number · Percentage of participants
Clinical Benefit Rate (CBR)
Percentage of participantsCohort 1 (V600E BRAF Negative)Cohort 2 (V600E BRAF Positive)
Determined by IRR31.2 (22.0 to 41.6)14.6 (8.0 to 23.7)
Determined by Investigator33.3 (23.9 to 43.9)20.2 (12.4 to 30.1)
SecondaryNumber of Participants With Adverse Events (AEs)/ Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Lenvatinib

Safety was assessed by monitoring and recording all AEs including all Common Terminology Criteria for Adverse Events (CTCAE) grades and SAEs; regular monitoring of hematology, clinical chemistry, and urine values; physical examinations; and regular measurement of vital signs, electrocardiograms (ECGs), and multi-gated acquisition (MUGA) scans or echocardiogram.

Time frame:
From date of treatment start up to 30 days after the last dose, or up to data cutoff (Cohort 1; 15 Jan 2012 and Cohort 2; 15 Apr 2013), up to approximately 2 years 9 months
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs)/ Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Lenvatinib
ParticipantsCohort 1 (V600E BRAF Negative)Cohort 2 (V600E BRAF Positive)
AEs9389
SAEs3936
SecondaryChange From Baseline in the Concentration of Clinical Biomarkers in Whole Blood

Blood samples were drawn at specific time points. Utilizing a standard protocol, the deoxyribonucleic acid (DNA) from whole blood was extracted and analyzed for specific biomarkers of absorption, distribution, metabolism, and excretion of lenvatinib. Some of the biomarkers analyzed included; Angiopoietin, Epidermal Growth Factor (EGF), Fibroblast Growth Factor (FGF), FMS Like Tyrosine Kinase 3 Ligand (Flt3l) Granulocyte Colony Stimulating Factor (G-CSF), Granulocyte Macro Colony Stimulating Factor (GM-CSF), Interleukin 1 Receptor Antagonist (IL-1RA), Interferon (IFN), Macrophage Inflammatory Protein (MIP) 1 alpha, Platelet Derived Growth Factor (PDGF), Stromal Cell Derived Factor (SDF) 1 alpha, Interleukin (IL), Transforming Growth Factor (TGF), Tumor Necrosis Factor (TNF), Vascular Endothelial Growth Factor (VEGF).

Time frame:
Cycle 1 Day 15 (C1 D15), Cycle 2 Day 1 (C2 D1), Cycle 3 Day 1 (C3 D1), Off-Treatment/Phase Visit 98 (V98)
Reported as:
Mean · pg/mL
Change From Baseline in the Concentration of Clinical Biomarkers in Whole Blood
pg/mLCohort 1 (V600E BRAF Negative)Cohort 2 (V600E BRAF Positive)
Angiopoietin 2 76 C1D15-1015.69 ± 946.596—
Angiopoietin 2 76 C2D1-832.29 ± 1257.287—
Angiopoietin 2 76 C3D1-923.82 ± 969.285—
Angiopoietin 2 76 V98-947.00 ± 825.037—
Angiopoietin 2 90 C1D15—-1225.322 ± 1950.4525
Angiopoietin 2 90 C2D1—-1100.235 ± 1378.4621
Angiopoietin 1 C1D15-3033.030 ± 8808.2059-2717.533 ± 16689.4536
Angiopoietin 1 C2D1-2802.306 ± 10202.7814-1743.569 ± 15546.4804
Angiopoietin 1 C3D1-859.021 ± 9994.6711—
Angiopoietin 1 V988107.400 ± 17740.0516—
Angiopoietin 2 C1D15-1462.552 ± 1541.8074-2154.269 ± 3560.0029
Angiopoietin 2 C2D1-1225.462 ± 1872.5841-1884.439 ± 2357.1979
Angiopoietin 2 C3D1-1255.485 ± 1738.0891—
Angiopoietin 2 V98-1374.183 ± 1158.2897—
CD40 Ligand C1D15-24020.778 ± 62788.2464-4678.661 ± 41191.7303
CD40 Ligand C2D1-22957.613 ± 73677.4378-7254.754 ± 37794.5541
CD40 Ligand C3D1-16700.900 ± 48016.0710—
CD40 Ligand V982192.177 ± 86909.9688—
EGF 2 C1D15-46.493 ± 101.0772-0.516 ± 219.9787
EGF 2 C2D1-39.636 ± 125.0664-29.803 ± 121.1705
EGF 2 C3D1-37.600 ± 113.8543—
EGF 2 V98-2.230 ± 191.4129—
EGF 59 C1D15-37.07 ± 81.051—
EGF 59 C2D1-31.58 ± 96.200—
EGF 59 C3D1-24.49 ± 93.102—
EGF 59 V9810.17 ± 137.755—
EGF 80 C1D15—-31.519 ± 126.2579
EGF 80 C2D1—-32.171 ± 121.7805
Eotaxin-4 C1D1551.456 ± 117.126646.538 ± 128.398
Eotaxin-4 C2D199.974 ± 207.024360.919 ± 114.6134
Eotaxin-4 C3D189.878 ± 108.6392—
Eotaxin-4 V98104.613 ± 157.7527—
FGF 2 C1D15-4.294 ± 51.39858.325 ± 136.3433
FGF 2 C2D1-8.085 ± 48.8273-8.003 ± 144.9054
FGF 2 C3D17.443 ± 45.7310—
FGF 2 V98-3.917 ± 62.3623—
FGF 23 C1D156.549 ± 22.5297—
FGF 23 C2D16.496 ± 27.2305—
FGF 23 C3D16.691 ± 24.5203—
FGF 23 V9813.430 ± 36.7130—
FGF 4 C1D15-24.226 ± 100.682350.369 ± 253.9626
FGF 4 C2D1-15.491 ± 104.999155.785 ± 264.4585
FGF 4 C3D15.283 ± 130.3452—
FGF 4 V9833.860 ± 185.4616—
FGF Basic Form C1D15-0.597 ± 18.685143.457 ± 224.9856
FGF Basic Form C2D1-1.212 ± 38.413164.237 ± 328.6676
FGF Basic Form C3D12.060 ± 29.2405—
FGF Basic Form V9818.384 ± 28.6214—
Flt3l C1D15-0.037 ± 32.5371-8.877 ± 23.0368
Flt3l C2D15.135 ± 28.0359-1.362 ± 39.2251
Flt3l C3D15.439 ± 24.1985—
Flt3l V9813.367 ± 17.7279—
Fractalkine C1D15-11.700 ± 94.511538.670 ± 237.5045
Fractalkine C2D1-1.175 ± 70.08584.663 ± 58.1950
Fractalkine C3D1-5.588 ± 116.3955—
Fractalkine V9815.838 ± 90.6004—
G-CSF C1D154.329 ± 20.83436.368 ± 61.7181
G-CSF C2D17.366 ± 32.555212.601 ± 72.5113
G-CSF C3D111.292 ± 24.1828—
G-CSF V9834.653 ± 101.7055—
GM-CSF C1D150.767 ± 16.931444.665 ± 220.9124
GM-CSF C2D14.371 ± 38.3355139.491 ± 725.0903
GM-CSF C3D110.036 ± 49.8538—
GM-CSF V98-1.495 ± 5.1831—
Growth Regulated Oncogene C1D15—-141.838 ± 410.3579
Growth Regulated Oncogene C2D1—-120.148 ± 456.3073
Hepatocyte Growth Factor C1D15102.527 ± 1309.4077-91.790 ± 781.2225
Hepatocyte Growth Factor C2D1-126.667 ± 693.2257-147.796 ± 411.1836
Hepatocyte Growth Factor C3D161.257 ± 1062.3266—
Hepatocyte Growth Factor V98404.700 ± 456.8130—
Interferon Gamma C1D154.072 ± 19.399433.743 ± 100.3678
Interferon Gamma C2D1-0.392 ± 14.8083-10.164 ± 170.9869
Interferon Gamma C3D12.986 ± 5.7591—
Interferon Gamma V982.455 ± 5.2255—
Interleukin 1 alpha C1D150.159 ± 7.944167.203 ± 200.9806
Interleukin 1 alpha C2D10.226 ± 8.2728-36.352 ± 198.1416
Interleukin 1 alpha C3D1-0.140 ± 13.7136—
Interleukin 1 Beta C1D150.279 ± 1.966859.768 ± 137.6657
Interleukin 1 Beta C2D11.198 ± 5.004427.690 ± 61.2456
Interleukin 1 Beta C3D11.882 ± 11.1737—
IL-1RA C1D1514.490 ± 63.586946.381 ± 132.3985
IL-1RA C2D120.295 ± 61.979938.131 ± 142.7521
IL-1RA C3D17.048 ± 30.9383—
IL-1RA V9884.614 ± 178.1590—
Interleukin 12 (p40) C1D1514.514 ± 73.98065.458 ± 28.8514
Interleukin 12 (p40) C2D116.052 ± 40.3849918.03 ± 3917.8689
Interleukin 12 (p40) C3D111.183 ± 36.3506—
Interleukin 12 (p40) V98-8.130 ± 5.7276—
Interleukin 12 (p70) C1D151.241 ± 18.842927.919 ± 62.8944
Interleukin 12 (p70) C2D1-5.622 ± 28.63817.820 ± 71.1505
Interleukin 12 (p70) C3D1-6.099 ± 19.5015—
Interleukin 12 (p70) V9811.275 ± 20.0182—
Interleukin 10 C1D15-5.170 ± 38.0092-7.611 ± 22.1926
Interleukin 10 C2D1-1.901 ± 33.62031.687 ± 72.7629
Interleukin 10 C3D14.136 ± 10.8185—
Interleukin 10 V98-28.065 ± 41.7547—
Interleukin 13 C1D150.961 ± 5.00668.574 ± 13.4754
Interleukin 13 C2D12.451 ± 7.63748.536 ± 18.5220
Interleukin 13 C3D15.404 ± 16.4719—
Interleukin 15 C1D150.128 ± 2.295785.619 ± 234.7106
Interleukin 15 C2D11.403 ± 4.1630574.776 ± 1709.9272
Interleukin 15 C3D1-0.178 ± 3.6993—
Interleukin 15 V983.930 ± NA—
Interleukin 17 C1D153.434 ± 8.64634.567 ± 12.1008
Interleukin 17 C2D11.264 ± 8.09633.035 ± 15.8736
Interleukin 17 C3D10.011 ± 3.4100—
Interleukin 17 V988.440 ± 11.7663—
Interleukin 2 C1D15-1.004 ± 7.1024173.878 ± 397.2754
Interleukin 2 C2D15.853 ± 20.3294191.410 ± 461.1991
Interleukin 2 C3D12.647 ± 19.5979—
Interleukin 4 C1D158.169 ± 30.030512.815 ± 77.4310
Interleukin 4 C2D120.167 ± 77.06197.815 ± 54.5735
Interleukin 4 C3D16.583 ± 20.3824—
Interleukin 5 C1D150.311 ± 1.13146.088 ± 7.5239
Interleukin 5 C2D10.205 ± 1.593111.382 ± 9.8663
Interleukin 5 C3D1-0.327 ± 1.1102—
Interleukin 6 C1D150.166 ± 6.87743.784 ± 30.0715
Interleukin 6 C2D14.778 ± 34.02545.524 ± 32.1205
Interleukin 6 C3D12.027 ± 7.3121—
Interleukin 6 V983.160 ± 6.6276—
Interleukin 7 C1D151.267 ± 7.37322.167 ± 8.8122
Interleukin 7 C2D12.413 ± 8.83675.744 ± 18.4339
Interleukin 7 C3D10.616 ± 5.0590—
Interleukin 7 V9820.760 ± 28.0439—
Interleukin 8 C1D15-5.801 ± 46.1572-20.769 ± 52.1135
Interleukin 8 C2D1-5.431 ± 43.4197-14.303 ± 57.9561
Interleukin 8 C3D1-7.348 ± 43.0509—
Interleukin 8 V9826.982 ± 32.7795—
IFN gamma Induced Protein 10 C1D15453.684 ± 1446.5825184.891 ± 501.5782
IFN gamma Induced Protein 10 C2D1246.194 ± 246.194306.075 ± 792.5621
IFN gamma Induced Protein 10 C3D1201.923 ± 483.5088—
IFN gamma Induced Protein 10 V98359.872 ± 501.1082—
Monocyte Chemotactic Protein 1 C1D150.733 ± 423.2721-101.580 ± 371.5381
Monocyte Chemotactic Protein 1 C2D1-19.036 ± 372.5242128.749 ± 541.1034
Monocyte Chemotactic Protein 1 C3D113.542 ± 370.3700—
Monocyte Chemotactic Protein 1 V98-128.627 ± 1234.5888—
MIP 1 alpha C1D15-1.842 ± 11.9129-0.320 ± 38.5273
MIP 1 alpha C2D1-2.098 ± 12.0121-0.473 ± 35.4447
MIP 1 alpha C3D1-1.167 ± 15.9038—
MIP 1 alpha V987.563 ± 7.8802—
MIP 1 beta C1D150.032 ± 20.14905.746 ± 64.1386
MIP 1 beta C2D1-1.198 ± 31.452231.277 ± 261.3460
MIP 1 beta C3D11.850 ± 15.208—
MIP 1 beta V987.518 ± 11.9566—
PDGF AA 31 P1 C1D15—-183.36 ± 2260.110
PDGF AA 31 P1 C2D1—-268.83 ± 2054.666
PDGF AB C1D15-36.637 ± 353.6898-121.278 ± 325.1308
PDGF AB C2D1-99.852 ± 338.5816-80.778 ± 363.1249
PDGF AB C3D1-7.702 ± 311.6834—
PDGF AB V98130.800 ± 382.6282—
PDGF BB C1D15-120.317 ± 1758.7655-567.664 ± 1385.6740
PDGF BB C2D1-435.311 ± 1961.7449-371.888 ± 1186.1
PDGF BB C3D1333.637 ± 1516.1506—
PDGF BB V98174.083 ± 3221.9009—
Placental Derived Growth Factor C1D1555.444 ± 55.067155.0671 ± 29.8457
Placental Derived Growth Factor C2D150.439 ± 58.257151.359 ± 76.6390
Placental Derived Growth Factor C3D161.080 ± 58.2969—
Placental Derived Growth Factor V98112.683 ± 110.3416—
Chemokine Ligand 5 C1D15—-2373.94 ± 46225.695
Chemokine Ligand 5 C2D1—551.64 ± 49492.450
SDF 1 alpha C1D15441.305 ± 385.8988506.768 ± 487.7603
SDF 1 alpha C2D1520.051 ± 510.8558647.435 ± 470.0962
SDF 1 alpha C3D1509.483 ± 550.4383—
SDF 1 alpha V98836.532 ± 686.4434—
Soluble IL2 Receptor alpha C1D15-25.869 ± 86.0991-414.669 ± 765.1544
Soluble IL2 Receptor alpha C2D1-13.695 ± 65.5643-290.918 ± 1023.3392
Soluble IL2 Receptor alpha C3D1-12.233 ± 31.5415—
Soluble IL2 Receptor alpha V98-19.238 ± 43.0942—
TGF alpha C1D15-0.874 ± 4.660521.148 ± 168.7766
TGF alpha C2D1-0.350 ± 6.5375-6.019 ± 24.3258
TGF alpha C3D11.165 ± 11.8825—
TGF alpha V982.590 ± 3.4672—
Tie-2 C1D15-2971.948 ± 2397.5234-3573.856 ± 2996.7139
Tie-2 C2D1-3447.692 ± 3577.1791-4088.214 ± 3191.9812
Tie-2 C3D1-2811.765 ± 3459.1934—
Tie-2 V98-1924.000 ± 3215.5684—
TNF alpha C1D15-0.233 ± 4.97471.451 ± 24.8216
TNF alpha C2D10.039 ± 3.95401.741 ± 15.0677
TNF alpha C3D10.614 ± 4.6336—
TNF alpha V983.027 ± 4.7343—
VEGF C1D15-13.294 ± 112.687110.709 ± 285.2533
VEGF C2D1-11.523 ± 122.6064-26.215 ± 239.4960
VEGF C3D116.732 ± 160.3096—
VEGF V98155.638 ± 352.8309—
VEGF A C1D1578.868 ± 174.801192.748 ± 273.6190
VEGF A C2D176.041 ± 194.1394140.664 ± 336.9135
VEGF A C3D1116.800 ± 233.1657—
VEGF A V98465.833 ± 515.7676—
VEGF D C1D150.953 ± 87.65133.404 ± 42.7585
VEGF D C2D1-9.776 ± 98.090511.043 ± 116.5445
VEGF D C3D19.894 ± 57.1140—
VEGF D V98-21.317 ± 88.6689—
VEGF Rec 1 C1D15593.613 ± 3109.3343-221.867 ± 799.9202
VEGF Rec 1 C2D1-3.971 ± 739.7875-243.661 ± 1031.2376
VEGF Rec 1 C3D1-209.863 ± 809.7744—
VEGF Rec 1 V98-15.567 ± 90.6274—
VEGF Rec 2 C1D15-10110.096 ± 5626.0125-8842.040 ± 6078.7151
VEGF Rec 2 C2D1-9369.165 ± 17982.0625-10676.563 ± 7064.0825
VEGF Rec 2 C3D1-11389.576 ± 10955.1596—
VEGF Rec 2 V98-9021.217 ± 5921.9619—
VEGF Rec 3 C1D15-1174.650 ± 2226.7893-2251.867 ± 3231.1485
VEGF Rec 3 C2D1-1320.738 ± 3138.3810-2523.257 ± 3550.7291
VEGF Rec 3 C3D1-1488.140 ± 3687.8774—
VEGF Rec 3 V98-1201.680 ± 2441.5741—
SecondarySummary of Plasma Concentration of Lenvatinib

Blood samples for the quantification of lenvatinib in plasma were obtained and processed using a standardized protocol. The lower limit of quantification was 0.25 ng/mL. Pharmacokinetic (PK) analysis was conducted using nonlinear mixed effects modeling. Descriptive statistics were used to summarize lenvatinib plasma concentration data.

Time frame:
Predose and 2 to 12 hours postdose at Cycle 1 Day 1 (C1D1), Cycle 1 Day 15 (C1D15), and Cycle 2 Day 1 (C2D1)
Reported as:
Mean · ng/mL
Summary of Plasma Concentration of Lenvatinib
ng/mLCohort 1 (V600E BRAF Negative)Cohort 2 (V600E BRAF Positive)
C1D1 Pre-dose0 ± 00 ± 0
C1D1 Post-dose229.6 ± 148.98287.6 ± 168.97
C1D15 Pre-dose56.8 ± 8271.9 ± 104.09
C1D15 Post-dose284.0 ± 141.71332.1 ± 221.98
C2D1 Pre-dose38.7 ± 32.9452.0 ± 48.73
C2D1 Post-dose244.5 ± 182.67270.4 ± 143.64

Adverse events

Collected over From date of administration of first dose up to 30 days after the last dose, or up to data cutoff (15 Jan 2012 and 15 Apr 2013 for Cohort 1 and Cohort 2, respectively), up to approximately 33 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 (V600E BRAF Negative)—39/93 (41.9%)93/93 (100%)
Cohort 2 (V600E BRAF Positive)—36/89 (40.4%)88/89 (98.9%)
Most frequent serious events
Showing 10 of 90
Most frequent serious events
EventCohort 1 (V600E BRAF Negative)Cohort 2 (V600E BRAF Positive)
HypertensionVascular disorders5/931/89
NauseaGastrointestinal disorders3/933/89
Abdominal painGastrointestinal disorders1/933/89
Deep vein thrombosisVascular disorders3/930/89
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/932/89
PneumoniaInfections and infestations2/932/89
Groin painMusculoskeletal and connective tissue disorders0/932/89
FatigueGeneral disorders0/932/89
General physical health deteriorationGeneral disorders0/932/89
PancreatitisGastrointestinal disorders2/930/89
Most frequent other events
Showing 10 of 65
Most frequent other events
EventCohort 1 (V600E BRAF Negative)Cohort 2 (V600E BRAF Positive)
FatigueGeneral disorders62/9341/89
HypertensionVascular disorders53/9348/89
NauseaGastrointestinal disorders48/9336/89
DiarrhoeaGastrointestinal disorders44/9326/89
Decreased appetiteMetabolism and nutrition disorders40/9330/89
VomitingGastrointestinal disorders36/9332/89
DysphoniaRespiratory, thoracic and mediastinal disorders26/9333/89
ConstipationGastrointestinal disorders25/9328/89
ArthralgiaMusculoskeletal and connective tissue disorders29/9320/89
HeadacheNervous system disorders29/9321/89

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort 1 (V600E BRAF Negative)Cohort 2 (V600E BRAF Positive)Total
Mean62.5 ± 11.7155.0 ± 14.1858.8 ± 13.47
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Cohort 1 (V600E BRAF Negative)Cohort 2 (V600E BRAF Positive)Total
Female293968
Male6450114
AJCC Melanoma Tumor, Node, Metastasis (TNM) Stage at Study Entry
AJCC Melanoma Tumor, Node, Metastasis (TNM) Stage at Study Entry(Participants)Cohort 1 (V600E BRAF Negative)Cohort 2 (V600E BRAF Positive)Total
Unresectable Stage III5712
Unresectable Stage IV8882170
08

Study locations

95 sites
  • Birmingham, Alabama, United States
  • Tucson, Arizona, United States
  • Los Angeles, California, United States
  • San Francisco, California, United States
  • Aurora, Colorado, United States
  • Boulder, Colorado, United States
  • Colorado Springs, Colorado, United States
  • Denver, Colorado, United States
  • Lakewood, Colorado, United States
  • Littleton, Colorado, United States
  • Lone Tree, Colorado, United States
  • Longmont, Colorado, United States
  • Parker, Colorado, United States
  • Thornton, Colorado, United States
  • Bonita Springs, Florida, United States
  • Bradenton, Florida, United States
  • Cape Coral, Florida, United States
  • Clearwater, Florida, United States
  • Englewood, Florida, United States
  • Fort Myers, Florida, United States
  • Gainesville, Florida, United States
  • Naples, Florida, United States
  • North Port, Florida, United States
  • Orlando, Florida, United States
  • Palm Harbor, Florida, United States
  • Port Charlotte, Florida, United States
  • Sarasota, Florida, United States
  • Sebring, Florida, United States
  • Tampa, Florida, United States
  • Venice, Florida, United States
  • Louisville, Kentucky, United States
  • Boston, Massachusetts, United States
  • Detroit, Michigan, United States
  • Burnsville, Minnesota, United States
  • Coon Rapids, Minnesota, United States
  • Edina, Minnesota, United States
  • Fridley, Minnesota, United States
  • Maplewood, Minnesota, United States
  • Minneapolis, Minnesota, United States
  • Saint Paul, Minnesota, United States
  • Woodbury, Minnesota, United States
  • Southaven, Mississippi, United States
  • Saint Louis, Missouri, United States
  • Henderson, Nevada, United States
  • Las Vegas, Nevada, United States
  • Lebanon, New Hampshire, United States
  • Morristown, New Jersey, United States
  • New York, New York, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Eugene, Oregon, United States
  • Portland, Oregon, United States
  • Springfield, Oregon, United States
  • Tualatin, Oregon, United States
  • Bethlehem, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Bartlett, Tennessee, United States
  • Franklin, Tennessee, United States
  • Gallatin, Tennessee, United States
  • Germantown, Tennessee, United States
  • Hermitage, Tennessee, United States
  • Lebanon, Tennessee, United States
  • Memphis, Tennessee, United States
  • Murfreesboro, Tennessee, United States
  • Nashville, Tennessee, United States
  • Smyrna, Tennessee, United States
  • Bedford, Texas, United States
  • Dallas, Texas, United States
  • Grapevine, Texas, United States
  • Houston, Texas, United States
  • Arlington, Virginia, United States
  • Fairfax, Virginia, United States
  • Gainesville, Virginia, United States
  • Leesburg, Virginia, United States
  • Winchester, Virginia, United States
  • Woodbridge, Virginia, United States
  • Vancouver, Washington, United States
  • Madison, Wisconsin, United States
  • Adelaide, Australia
  • Malvern, Australia
  • Newcastle, Australia
  • North Sydney, Australia
  • Perth, Australia
  • Westmead, Australia
  • Essen, Germany
  • Hannover, Germany
  • Heidelberg, Germany
  • Kiel, Germany
  • Mainz, Germany
  • Tubingen, Germany
  • Glasgow, United Kingdom
  • London, United Kingdom
  • Nottingham, United Kingdom
  • Surrey, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2010 to primary completion in Apr 2013, 32 months.

Results were first posted in Mar 2016, 2 years 11 months after primary completion.

Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 32 months is close to that.

Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2010
First posted
Jun 4, 2010
StartActual
Aug 2010
Primary completionActual
Apr 2013
CompletionActual
Nov 2014
Results first posted
Mar 16, 2016
Last update
Nov 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01136967
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Jun 4, 2010
Start date
Aug 2010
Primary completion
Apr 2013
Completion
Nov 2014
Results posted
Mar 16, 2016
Last update
Nov 13, 2019

Study contacts

Eisai US Medical Services
study director · Eisai Limited

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion